文献速递脑血管病

降低低密度脂蛋白胆固醇、缺血性卒中与小血管病脑影像生物标志物:一项孟德尔随机化研究

LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
PubMed 文献 · Stroke · 2024-04-04

本研究采用两样本孟德尔随机化方法,评估遗传代理的低密度脂蛋白胆固醇(LDL-c)及三种临床获批降LDL-c药物靶点(HMGCR、PCSK9、NPC1L1)对缺血性卒中亚型及小血管卒中相关脑影像生物标志物的影响。全基因组分析显示遗传预测较低LDL-c与任何卒中、缺血性卒中及大动脉粥样硬化性卒中风险降低显著相关;药物靶点分析显示通过NPC1L1抑制遗传代理降低LDL-c与血管周围间隙概率降低(每降低1 mg/dL的比值比0.79,95%CI 0.67-0.93)及小血管卒中概率降低(比值比0.29,95%CI 0.10-0.85)相关。结论提示通过NPC1L1抑制降低LDL-c对小血管卒中风险可能具有保护作用。

要点

  • 遗传预测较低LDL-c与任何卒中、缺血性卒中及大动脉粥样硬化性卒中风险降低显著相关。
  • 遗传预测LDL-c与小血管卒中、心源性栓塞性卒中及白质高信号体积、血管周围间隙无显著关联。
  • 通过NPC1L1抑制降低LDL-c与小血管卒中及血管周围间隙概率降低相关。

核心结论

  • 本研究提供证据支持通过NPC1L1抑制降低LDL-c对血管周围间隙和小血管卒中风险可能具有保护作用,并提示小血管卒中的新治疗靶点。

研究设计与样本

  • 采用两样本孟德尔随机化方法,评估遗传代理的LDL-c及三种临床获批降LDL-c药物靶点(HMGCR、PCSK9、NPC1L1)对卒中亚型及小血管卒中相关脑影像生物标志物的影响。

主要发现

  • 全基因组孟德尔随机化分析中,遗传预测较低LDL-c与任何卒中、缺血性卒中及大动脉粥样硬化性卒中风险降低显著相关。
  • 遗传预测LDL-c与心源性栓塞性卒中、小血管卒中、血管周围间隙及白质高信号体积的关联在本研究中未发现显著。
  • 药物靶点孟德尔随机化分析中,通过NPC1L1抑制遗传代理降低LDL-c与血管周围间隙概率降低相关(每降低1 mg/dL的比值比0.79,95%CI 0.67-0.93)。
  • 通过NPC1L1抑制遗传代理降低LDL-c与小血管卒中概率降低相关(比值比0.29,95%CI 0.10-0.85)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of lipid-lowering drug targets on different ischemic stroke subtypes are not fully understood. We aimed to explore the mechanisms by which lipid-lowering drug targets differentially affect the risk of ischemic stroke subtypes and their underlying pathophysiology. METHODS: Using a 2-sample Mendelian randomization approach, we assessed the effects of genetically proxied low-density lipoprotein cholesterol (LDL-c) and 3 clinically approved LDL-lowering drugs (HMGCR [3-hydroxy-3-methylglutaryl-CoA reductase], PCSK9 [proprotein convertase subtilisin/kexin type 9], and NPC1L1 [Niemann-Pick C1-Like 1]) on stroke subtypes and brain imaging biomarkers associated with small vessel stroke (SVS), including white matter hyperintensity volume and perivascular spaces. RESULTS: In genome-wide Mendelian randomization analyses, lower genetically predicted LDL-c was significantly associated with a reduced risk of any stroke, ischemic stroke, and large artery stroke, supporting previous findings. Significant associations between genetically predicted LDL-c and cardioembolic stroke, SVS, and biomarkers, perivascular space and white matter hyperintensity volume, were not identified in this study. In drug-target Mendelian randomization analysis, genetically proxied reduced LDL-c through NPC1L1 inhibition was associated with lower odds of perivascular space (odds ratio per 1-mg/dL decrease, 0.79 [95% CI, 0.67-0.93]) and with lower odds of SVS (odds ratio, 0.29 [95% CI, 0.10-0.85]). CONCLUSIONS: This study provides supporting evidence of a potentially protective effect of LDL-c lowering through NPC1L1 inhibition on perivascular space and SVS risk, highlighting novel therapeutic targets for SVS.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Dib MJ, Zagkos L, Meena D, et al. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study. Stroke. 2024. PMID: 38572634. doi:10.1161/STROKEAHA.123.045297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。